Home
Random
Nearby
Log in
Settings
Donate
About Wikidata
Disclaimers
Search
(Q33990246)
Watch
English
Drug therapy for multiple sclerosis.
scientific article
In more languages
edit
Statements
instance of
scholarly article
1 reference
stated in
Europe PubMed Central
PMC publication ID
4119143
reference URL
https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24756629%20AND%20SRC:MED&resulttype=core&format=json
retrieved
15 March 2020
title
Drug therapy for multiple sclerosis
(English)
1 reference
stated in
Europe PubMed Central
PMC publication ID
4119143
reference URL
https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24756629%20AND%20SRC:MED&resulttype=core&format=json
retrieved
15 March 2020
author
Marco Rovaris
series ordinal
2
1 reference
stated in
Europe PubMed Central
PMC publication ID
4119143
reference URL
https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24756629%20AND%20SRC:MED&resulttype=core&format=json
retrieved
15 March 2020
author name string
Eleonora Tavazzi
series ordinal
1
1 reference
stated in
Europe PubMed Central
PMC publication ID
4119143
reference URL
https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24756629%20AND%20SRC:MED&resulttype=core&format=json
retrieved
15 March 2020
Loredana La Mantia
series ordinal
3
1 reference
stated in
Europe PubMed Central
PMC publication ID
4119143
reference URL
https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24756629%20AND%20SRC:MED&resulttype=core&format=json
retrieved
15 March 2020
language of work or name
English
0 references
publication date
22 April 2014
1 reference
stated in
Europe PubMed Central
PMC publication ID
4119143
reference URL
https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24756629%20AND%20SRC:MED&resulttype=core&format=json
retrieved
15 March 2020
published in
Canadian Medical Association Journal
1 reference
stated in
Europe PubMed Central
PMC publication ID
4119143
reference URL
https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24756629%20AND%20SRC:MED&resulttype=core&format=json
retrieved
15 March 2020
volume
186
1 reference
stated in
Europe PubMed Central
PMC publication ID
4119143
reference URL
https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24756629%20AND%20SRC:MED&resulttype=core&format=json
retrieved
15 March 2020
issue
11
1 reference
stated in
Europe PubMed Central
PMC publication ID
4119143
reference URL
https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24756629%20AND%20SRC:MED&resulttype=core&format=json
retrieved
15 March 2020
page(s)
833-840
1 reference
stated in
Europe PubMed Central
PMC publication ID
4119143
reference URL
https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24756629%20AND%20SRC:MED&resulttype=core&format=json
retrieved
15 March 2020
cites work
Oral versus intravenous steroids for treatment of relapses in multiple sclerosis
1 reference
stated in
PubMed Central
reference URL
https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4119143
retrieved
28 July 2018
Alemtuzumab versus interferon beta 1a as first-line treatment for patients with relapsing-remitting multiple sclerosis: a randomised controlled phase 3 trial
1 reference
stated in
PubMed Central
reference URL
https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4119143
retrieved
28 July 2018
Alemtuzumab for patients with relapsing multiple sclerosis after disease-modifying therapy: a randomised controlled phase 3 trial
1 reference
stated in
PubMed Central
reference URL
https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4119143
retrieved
28 July 2018
Pregnancy and fetal outcomes after Glatiramer Acetate exposure in patients with multiple sclerosis: a prospective observational multicentric study
1 reference
stated in
PubMed Central
reference URL
https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4119143
retrieved
28 July 2018
The mechanism of action of glatiramer acetate in multiple sclerosis and beyond
1 reference
stated in
PubMed Central
reference URL
https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4119143
retrieved
28 July 2018
Placebo-controlled phase 3 study of oral BG-12 for relapsing multiple sclerosis
1 reference
stated in
PubMed Central
reference URL
https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4119143
retrieved
28 July 2018
Association between use of interferon beta and progression of disability in patients with relapsing-remitting multiple sclerosis
1 reference
stated in
PubMed Central
reference URL
https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4119143
retrieved
28 July 2018
Impact of fingolimod therapy on magnetic resonance imaging outcomes in patients with multiple sclerosis
1 reference
stated in
PubMed Central
reference URL
https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4119143
retrieved
28 July 2018
Risk of natalizumab-associated progressive multifocal leukoencephalopathy
1 reference
stated in
PubMed Central
reference URL
https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4119143
retrieved
28 July 2018
Clinically isolated syndromes
1 reference
stated in
PubMed Central
reference URL
https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4119143
retrieved
28 July 2018
Interferon beta for secondary progressive multiple sclerosis
1 reference
stated in
PubMed Central
reference URL
https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4119143
retrieved
28 July 2018
Mechanisms of fingolimod's efficacy and adverse effects in multiple sclerosis
1 reference
stated in
PubMed Central
reference URL
https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4119143
retrieved
28 July 2018
Determinants of interferon β efficacy in patients with multiple sclerosis
1 reference
stated in
PubMed Central
reference URL
https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4119143
retrieved
28 July 2018
Recommendations for clinical use of data on neutralising antibodies to interferon-beta therapy in multiple sclerosis
1 reference
stated in
PubMed Central
reference URL
https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4119143
retrieved
28 July 2018
Glatiramer acetate for multiple sclerosis
1 reference
stated in
PubMed Central
reference URL
https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4119143
retrieved
28 July 2018
Evidence Report: The efficacy and safety of mitoxantrone (Novantrone) in the treatment of multiple sclerosis: Report of the Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology
1 reference
stated in
PubMed Central
reference URL
https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4119143
retrieved
28 July 2018
Continuous long-term immunomodulatory therapy in relapsing multiple sclerosis: results from the 15-year analysis of the US prospective open-label study of glatiramer acetate
1 reference
stated in
PubMed Central
reference URL
https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4119143
retrieved
28 July 2018
A placebo-controlled trial of oral fingolimod in relapsing multiple sclerosis
1 reference
stated in
PubMed Central
reference URL
https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4119143
retrieved
28 July 2018
Alemtuzumab vs. interferon beta-1a in early multiple sclerosis
1 reference
stated in
PubMed Central
reference URL
https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4119143
retrieved
28 July 2018
Comparison of subcutaneous interferon beta-1a with glatiramer acetate in patients with relapsing multiple sclerosis (the REbif vs Glatiramer Acetate in Relapsing MS Disease [REGARD] study): a multicentre, randomised, parallel, open-label trial
1 reference
stated in
PubMed Central
reference URL
https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4119143
retrieved
28 July 2018
Mechanisms of action of disease-modifying agents and brain volume changes in multiple sclerosis
1 reference
stated in
PubMed Central
reference URL
https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4119143
retrieved
28 July 2018
Corticosteroids for the long-term treatment in multiple sclerosis
1 reference
stated in
PubMed Central
reference URL
https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4119143
retrieved
28 July 2018
Azathioprine for multiple sclerosis
1 reference
stated in
PubMed Central
reference URL
https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4119143
retrieved
28 July 2018
Glatiramer acetate in primary progressive multiple sclerosis: results of a multinational, multicenter, double-blind, placebo-controlled trial
1 reference
stated in
PubMed Central
reference URL
https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4119143
retrieved
28 July 2018
Cyclophosphamide for multiple sclerosis
1 reference
stated in
PubMed Central
reference URL
https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4119143
retrieved
28 July 2018
Secondary progressive multiple sclerosis: current knowledge and future challenges
1 reference
stated in
PubMed Central
reference URL
https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4119143
retrieved
28 July 2018
Mitoxantrone for multiple sclerosis
1 reference
stated in
PubMed Central
reference URL
https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4119143
retrieved
28 July 2018
The mechanism of action of methylprednisolone in the treatment of multiple sclerosis
1 reference
stated in
PubMed Central
reference URL
https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4119143
retrieved
28 July 2018
Effect of early interferon treatment on conversion to definite multiple sclerosis: a randomised study
1 reference
stated in
PubMed Central
reference URL
https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4119143
retrieved
28 July 2018
European/Canadian multicenter, double-blind, randomized, placebo-controlled study of the effects of glatiramer acetate on magnetic resonance imaging--measured disease activity and burden in patients with relapsing multiple sclerosis. European/Canadi
1 reference
stated in
PubMed Central
reference URL
https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4119143
retrieved
28 July 2018
Corticosteroids or ACTH for acute exacerbations in multiple sclerosis
1 reference
stated in
PubMed Central
reference URL
https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4119143
retrieved
28 July 2018
Intramuscular interferon beta-1a therapy initiated during a first demyelinating event in multiple sclerosis. CHAMPS Study Group
1 reference
stated in
PubMed Central
reference URL
https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4119143
retrieved
28 July 2018
Therapeutic effect of mitoxantrone combined with methylprednisolone in multiple sclerosis: a randomised multicentre study of active disease using MRI and clinical criteria
1 reference
stated in
PubMed Central
reference URL
https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4119143
retrieved
28 July 2018
Intramuscular interferon beta-1a for disease progression in relapsing multiple sclerosis. The Multiple Sclerosis Collaborative Research Group (MSCRG)
1 reference
stated in
PubMed Central
reference URL
https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4119143
retrieved
28 July 2018
Interferon beta-1b is effective in relapsing-remitting multiple sclerosis. II. MRI analysis results of a multicenter, randomized, double-blind, placebo-controlled trial. UBC MS/MRI Study Group and the IFNB Multiple Sclerosis Study Group
1 reference
stated in
PubMed Central
reference URL
https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4119143
retrieved
28 July 2018
Copolymer 1 reduces relapse rate and improves disability in relapsing-remitting multiple sclerosis: results of a phase III multicenter, double-blind placebo-controlled trial. The Copolymer 1 Multiple Sclerosis Study Group
1 reference
stated in
PubMed Central
reference URL
https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4119143
retrieved
28 July 2018
A pilot trial of Cop 1 in exacerbating-remitting multiple sclerosis
1 reference
stated in
PubMed Central
reference URL
https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4119143
retrieved
28 July 2018
Scoring treatment response in patients with relapsing multiple sclerosis.
1 reference
stated in
PubMed Central
reference URL
https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4119143
retrieved
29 October 2018
Clinical relevance of serum natalizumab concentration and anti-natalizumab antibodies in multiple sclerosis.
1 reference
stated in
PubMed Central
reference URL
https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4119143
retrieved
29 October 2018
Relationship between early clinical characteristics and long term disability outcomes: 16 year cohort study (follow-up) of the pivotal interferon β-1b trial in multiple sclerosis.
1 reference
stated in
PubMed Central
reference URL
https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4119143
retrieved
29 October 2018
Randomized trial of oral teriflunomide for relapsing multiple sclerosis.
1 reference
stated in
PubMed Central
reference URL
https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4119143
retrieved
29 October 2018
Natalizumab-associated progressive multifocal leukoencephalopathy in patients with multiple sclerosis: lessons from 28 cases
1 reference
stated in
PubMed Central
reference URL
https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4119143
retrieved
29 October 2018
A short-term randomized MRI study of high-dose oral vs intravenous methylprednisolone in MS.
1 reference
stated in
PubMed Central
reference URL
https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4119143
retrieved
29 October 2018
Rituximab in patients with primary progressive multiple sclerosis: results of a randomized double-blind placebo-controlled multicenter trial.
1 reference
stated in
PubMed Central
reference URL
https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4119143
retrieved
29 October 2018
Real-life impact of early interferon beta therapy in relapsing multiple sclerosis.
1 reference
stated in
PubMed Central
reference URL
https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4119143
retrieved
29 October 2018
Effect of glatiramer acetate on conversion to clinically definite multiple sclerosis in patients with clinically isolated syndrome (PreCISe study): a randomised, double-blind, placebo-controlled trial
1 reference
stated in
PubMed Central
reference URL
https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4119143
retrieved
29 October 2018
250 microg or 500 microg interferon beta-1b versus 20 mg glatiramer acetate in relapsing-remitting multiple sclerosis: a prospective, randomised, multicentre study
1 reference
stated in
PubMed Central
reference URL
https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4119143
retrieved
29 October 2018
Treatment with interferon beta-1b delays conversion to clinically definite and McDonald MS in patients with clinically isolated syndromes.
1 reference
stated in
PubMed Central
reference URL
https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4119143
retrieved
29 October 2018
A randomized, placebo-controlled trial of natalizumab for relapsing multiple sclerosis
1 reference
stated in
PubMed Central
reference URL
https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4119143
retrieved
29 October 2018
Interferon beta promotes nerve growth factor secretion early in the course of multiple sclerosis
1 reference
stated in
PubMed Central
reference URL
https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4119143
retrieved
29 October 2018
Effect of natalizumab on conversion of gadolinium enhancing lesions to T1 hypointense lesions in relapsing multiple sclerosis
1 reference
stated in
PubMed Central
reference URL
https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4119143
retrieved
29 October 2018
Effects of IV methylprednisolone on brain atrophy in relapsing-remitting MS.
1 reference
stated in
PubMed Central
reference URL
https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4119143
retrieved
29 October 2018
Change in the clinical activity of multiple sclerosis after treatment switch for suboptimal response
1 reference
stated in
PubMed Central
reference URL
https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4119143
retrieved
29 October 2018
Natalizumab treatment in multiple sclerosis: marked decline of chemokines and cytokines in cerebrospinal fluid
1 reference
stated in
PubMed
reference URL
https://pubmed.ncbi.nlm.nih.gov/24756629
retrieved
12 December 2020
based on heuristic
inferred from PubMed ID database lookup
Placebo-controlled multicentre randomised trial of interferon beta-1b in treatment of secondary progressive multiple sclerosis. European Study Group on interferon beta-1b in secondary progressive MS
1 reference
stated in
PubMed
reference URL
https://pubmed.ncbi.nlm.nih.gov/24756629
retrieved
12 December 2020
based on heuristic
inferred from PubMed ID database lookup
Randomised double-blind placebo-controlled study of interferon beta-1a in relapsing/remitting multiple sclerosis. PRISMS (Prevention of Relapses and Disability by Interferon beta-1a Subcutaneously in Multiple Sclerosis) Study Group
1 reference
stated in
PubMed
reference URL
https://pubmed.ncbi.nlm.nih.gov/24756629
retrieved
12 December 2020
based on heuristic
inferred from PubMed ID database lookup
IM interferon beta-1a delays definite multiple sclerosis 5 years after a first demyelinating event
1 reference
stated in
PubMed
reference URL
https://pubmed.ncbi.nlm.nih.gov/24756629
retrieved
12 December 2020
based on heuristic
inferred from PubMed ID database lookup
Association between immediate initiation of intramuscular interferon beta-1a at the time of a clinically isolated syndrome and long-term outcomes: a 10-year follow-up of the Controlled High-Risk Avonex Multiple Sclerosis Prevention Study in Ongoing
1 reference
stated in
PubMed
reference URL
https://pubmed.ncbi.nlm.nih.gov/24756629
retrieved
12 December 2020
based on heuristic
inferred from PubMed ID database lookup
Selective immunomodulation by the antineoplastic agent mitoxantrone. I. Suppression of B lymphocyte function
1 reference
stated in
PubMed
reference URL
https://pubmed.ncbi.nlm.nih.gov/24756629
retrieved
12 December 2020
based on heuristic
inferred from PubMed ID database lookup
Interferon beta-1b is effective in relapsing-remitting multiple sclerosis. I. Clinical results of a multicenter, randomized, double-blind, placebo-controlled trial. The IFNB Multiple Sclerosis Study Group
1 reference
stated in
PubMed
reference URL
https://pubmed.ncbi.nlm.nih.gov/24756629
retrieved
12 December 2020
based on heuristic
inferred from PubMed ID database lookup
Identifiers
DOI
10.1503/CMAJ.130727
1 reference
stated in
Europe PubMed Central
PMC publication ID
4119143
reference URL
https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24756629%20AND%20SRC:MED&resulttype=core&format=json
retrieved
15 March 2020
PMC publication ID
4119143
1 reference
stated in
Europe PubMed Central
PMC publication ID
4119143
reference URL
https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24756629%20AND%20SRC:MED&resulttype=core&format=json
retrieved
15 March 2020
PubMed publication ID
24756629
1 reference
stated in
Europe PubMed Central
PMC publication ID
4119143
reference URL
https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24756629%20AND%20SRC:MED&resulttype=core&format=json
retrieved
15 March 2020
ResearchGate publication ID
261802329
0 references
Sitelinks
Wikipedia
(0 entries)
edit
Wikibooks
(0 entries)
edit
Wikinews
(0 entries)
edit
Wikiquote
(0 entries)
edit
Wikisource
(0 entries)
edit
Wikiversity
(0 entries)
edit
Wikivoyage
(0 entries)
edit
Wiktionary
(0 entries)
edit
Multilingual sites
(0 entries)
edit